Protection against autoimmune myocarditis by gene transfer of interleukin-10 by electroporation

被引:64
作者
Watanabe, K
Nakazawa, M
Fuse, K
Hanawa, M
Kodama, M
Aizawa, Y
Ohnuki, T
Gejyo, F
Maruyama, H
Miyazaki, J
机构
[1] Niigata Coll Pharm, Dept Clin Pharmacol, Niigata 9502081, Japan
[2] Niigata Coll Pharm, Dept Pharmacol, Niigata 9502081, Japan
[3] Niigata Univ, Sch Med, Sch Hlth Sci, Dept Med Technol, Niigata, Japan
[4] NIigata Grad Sch Med & Dent Sci, Div Clin Nephrol & Rheumatol, Niigata, Japan
[5] Osaka Univ, Grad Sch Med, Dept Nutr & Physiol Chem, Osaka, Japan
关键词
interleukins; myocarditis; gene therapy; immune system; cardiomyopathy;
D O I
10.1161/hc3501.096190
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Although immunosuppressive therapy for myocarditis has attracted a great deal of attention, its effectiveness is controversial. Interleukin (IL)-10 has a variety of immunomodulatory properties. Among the nonviral techniques for gene transfer in vivo, the direct injection of plasmid DNA into muscle is simple, inexpensive, and safe. Methods and Results-We examined the applicability of murine IL-10 (mIL-10) gene transfer to the treatment of rats with experimental autoimmune myocarditis. Nine-week-old Lewis rats were inoculated with pig myosin (day 0). A plasmid vector expressing mIL-10 cDNA (800 mug per rat) was transferred into the tibialis anterior muscles by electroporation 3 times (5 days before immunization and at days 4 and 13); control rats received empty plasmid. Electroporation increased the serum mIL-10 levels to >250 pg/mL. The 21-day survive rate in rats treated with mIL-10 cDNA was higher (15 of 15; 100%) than that of the control group (9 of 15; 60%). Furthermore, mIL-10 treatment significantly attenuated myocardial lesions and improved hemodynamic parameters. Conclusions-These findings showed that gene transfer into muscle by electroporation in vivo is an effective means of delivery of IL-10 for the treatment of autoimmune myocarditis.
引用
收藏
页码:1098 / 1100
页数:3
相关论文
共 14 条
[1]   Gene transfer into muscle by electroporation in vivo [J].
Aihara, H ;
Miyazaki, J .
NATURE BIOTECHNOLOGY, 1998, 16 (09) :867-870
[2]   GIANT-CELL VERSUS LYMPHOCYTIC MYOCARDITIS - A COMPARISON OF THEIR CLINICAL-FEATURES AND LONG-TERM OUTCOMES [J].
DAVIDOFF, R ;
PALACIOS, I ;
SOUTHERN, J ;
FALLON, JT ;
NEWELL, J ;
DEC, GW .
CIRCULATION, 1991, 83 (03) :953-961
[3]   ACTIVE MYOCARDITIS IN THE SPECTRUM OF ACUTE DILATED CARDIOMYOPATHIES - CLINICAL-FEATURES, HISTOLOGIC CORRELATES, AND CLINICAL OUTCOME [J].
DEC, GW ;
PALACIOS, IF ;
FALLON, JT ;
ARETZ, HT ;
MILLS, J ;
LEE, DCS ;
JOHNSON, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (14) :885-890
[4]   2 TYPES OF MOUSE T-HELPER CELL .4. TH2 CLONES SECRETE A FACTOR THAT INHIBITS CYTOKINE PRODUCTION BY TH1 CLONES [J].
FIORENTINO, DF ;
BOND, MW ;
MOSMANN, TR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (06) :2081-2095
[5]   In vivo gene electroinjection and expression in rat liver [J].
Heller, R ;
Jaroszeski, M ;
Atkin, A ;
Moradpour, D ;
Gilbert, R ;
Wands, J ;
Nicolau, C .
FEBS LETTERS, 1996, 389 (03) :225-228
[6]   RAT DILATED CARDIOMYOPATHY AFTER AUTOIMMUNE GIANT-CELL MYOCARDITIS [J].
KODAMA, M ;
HANAWA, H ;
SAEKI, M ;
HOSONO, H ;
INOMATA, T ;
SUZUKI, K ;
SHIBATA, A .
CIRCULATION RESEARCH, 1994, 75 (02) :278-284
[7]   A NOVEL EXPERIMENTAL-MODEL OF GIANT-CELL MYOCARDITIS INDUCED IN RATS BY IMMUNIZATION WITH CARDIAC MYOSIN FRACTION [J].
KODAMA, M ;
MATSUMOTO, Y ;
FUJIWARA, M ;
MASANI, F ;
IZUMI, T ;
SHIBATA, A .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1990, 57 (02) :250-262
[8]   In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13 [J].
Lentsch, AB ;
Shanley, TP ;
Sarma, V ;
Ward, PA .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (10) :2443-2448
[9]   TH1 AND TH2 CD4(+) T-CELLS IN THE PATHOGENESIS OF ORGAN-SPECIFIC AUTOIMMUNE-DISEASES [J].
LIBLAU, RS ;
SINGER, SM ;
MCDEVITT, HO .
IMMUNOLOGY TODAY, 1995, 16 (01) :34-38
[10]   Continuous erythropoietin delivery by muscle-targeted gene transfer using in vivo electroporation [J].
Maruyama, H ;
Sugawa, M ;
Moriguchi, Y ;
Imazeki, I ;
Ishikawa, Y ;
Ataka, K ;
Hasegawa, S ;
Ito, Y ;
Higuchi, N ;
Kazama, JJ ;
Gejyo, F ;
Miyazaki, JI .
HUMAN GENE THERAPY, 2000, 11 (03) :429-437